Explore the most recent data on the drug situation in Europe provided by the EU Member States. These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format.
We work closely with the 27 EU Member States plus Norway and Türkiye, candidates and potential candidates to the EU, the European Neighbourhood Policy countries and other third countries.
We have developed a systemic approach that brings together the human networks, processes and scientific tools necessary for collecting, analysing and reporting on the many aspects of the European drugs phenomenon.
Unlocking The Potential Of GLP-1 Medications Beyond Weight Loss Ozempic Mrna
Location
Lisbon
Publication date
Reference
News release
In United States Publish Post Time: 2025-08-22
Did you know that popular diabetes and weight-loss drugs could also reduce risks for mental health issues and some cancers?
GLP-1 medications, known for weight loss and diabetes management, reveal surprising benefits for substance abuse disorders and mental health.,The study identifies 42 health outcomes where GLP-1 users see reduced risks, emphasizing their broader medical benefits.,Significantly, the drugs may decrease risks for serious conditions like liver failure and cardiac arrest while increasing some gastrointestinal issues.,Patients on GLP-1 medications reported lower risks of pneumonia and some infections, showcasing potential protective effects.,Mind-blowing results include reduced risks of psychosis and even some cancers, suggesting a new angle on these drugs' functions.,However, the drugs also come with risks—most notably gastrointestinal symptoms like nausea and digestive issues.,Dr. Ziyad Al-Aly advises anyone considering these medications to consult their healthcare provider for personalized risk assessments.,This pioneering study paints a broader picture, hinting at future possibilities for treating various health issues with GLP-1 medications.
#GLP1Medications, #HealthBenefits, #WeightLossAdvancements
Unlocking The Potential Of GLP-1 Medications Beyond Weight Loss For Country: United States. City: Killeen, New Haven, Ontario, Waterbury, Yonkers
To schedule interviews, obtain informed comment, request written contributions or receive the latest news on the agency, please contact our media relations sector:
Kathy Robertson
Principal manager
Media relations and corporate communication